The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial: study design and rationale


Harrington R. A. , Van de Werf F., Armstrong P. W. , Aylward P., Veltri E., Mahaffey K. W. , ...Daha Fazla

AMERICAN HEART JOURNAL, cilt.158, sa.3, ss.327-338, 2009 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 158 Konu: 3
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1016/j.ahj.2009.07.001
  • Dergi Adı: AMERICAN HEART JOURNAL
  • Sayfa Sayıları: ss.327-338

Özet

Background The protease-activated receptor 1 (PAR-1), the main platelet receptor for thrombin, represents a novel target for treatment of arterial thrombosis, and SCH 530348 is an orally active, selective, competitive PAR-1 antagonist. We designed TRA.CER to evaluate the efficacy and safety of SCH 530348 compared with placebo in addition to standard of care in patients with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS) and high-risk features.